预约演示
更新于：2026-04-21
RSVpreF
呼吸道合胞病毒疫苗（辉瑞大药厂）
更新于：2026-04-21
概要
基本信息
药物类型 预防性疫苗 |
别名 recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer)、Respiratory Syncytial Virus Vaccine、PF 06928316 + [4] |
作用方式 调节剂 |
作用机制 Respiratory syncytial virus F protein调节剂(呼吸道合胞病毒F蛋白调节剂) |
非在研适应症- |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (2023-01-04), |
最高研发阶段(中国)暂停 |
特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国) |
登录后查看时间轴
关联
34
项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的临床试验NCT07445763
Real-world Effectiveness of maTernAl RSVpreF vaccInation Against RSV-associated Acute Respiratory ilLness in Infants in BrAzil (TARSILA Study): a Multicentre, Prospective, Test-negative, Case-Control Study
The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.
开始日期2026-04-30 |
申办/合作机构 Innovea Medical Ltd. [+1] |
NCT07235397
Evaluating the Benefits Of RSV MaternaL vAccination Using a Scottish National Dataset.
This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.
开始日期2026-04-01 |
申办/合作机构 |
NCT07279298
Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection Associated With Respiratory Syncytial Virus-RSV- in Infants Under 6 Months of Age in Bogotá: a Case-control Study With a Negative Test Design
This study aims to evaluate the real-world effectiveness of two preventive immunization strategies against Respiratory Syncytial Virus (RSV)-associated severe acute respiratory infection in infants less than six months of age in Bogotá, Colombia. The strategies include maternal vaccination with RSVpreF administered between 28 and 36 weeks of gestation and neonatal immunization with nirsevimab for infants born to mothers who did not receive RSVpreF during pregnancy. Using a test-negative case-control design embedded in the city's sentinel surveillance system, infants hospitalized for severe respiratory infection will be systematically tested for RSV. Comparative vaccine effectiveness will be estimated to determine the impact of maternal RSV vaccination and neonatal monoclonal antibody immunization on RSV-associated hospitalizations, intensive care admissions, and mortality. The study will generate real-world evidence to inform local and regional public health decisions and guide the implementation of cost-effective hybrid immunization strategies against RSV in middle-income settings.
开始日期2026-02-01 |
申办/合作机构- |
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的临床结果
登录后查看更多信息
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的转化医学
登录后查看更多信息
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的专利（医药）
登录后查看更多信息
416
项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的文献（医药）2026-12-31·Human Vaccines & Immunotherapeutics
Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada
Article
作者: Moss, Stephana Julia ; Lee, Janet S W ; Vadlamudi, Nirma Khatri ; Castillo, Eliana ; MacDonald, Shannon E ; Dubé, Ève ; Bolotin, Shelly ; Halperin, Scott A ; Fitzpatrick, Tiffany ; Manca, Terra ; Greyson, Devon ; MacDonald, Jade ; Buchan, Sarah A ; Comeau, Jeannette L ; Papenburg, Jesse ; Parsons Leigh, Jeanna ; Blanchard, Wade ; Halperin, Donna ; Brousseau, Nicholas ; Langley, Joanne M ; Brundin-Mather, Rebecca
Two new RSV immunization products exist for infants: a prenatal vaccine (RSVpreF) and a long-acting monoclonal antibody for infants (nirsevimab). While both showed promise in clinical trials, implementation has varied across jurisdictions. Before rollout in Canada, we conducted an anonymized, online survey with a nationally representative sample of 1,015 expectant and recent birth parents. The primary outcome was product acceptability (disagree, undecided, agree). Odds ratios (ORs) and 95% confidence intervals (CIs) identified factors associated with agreement or indecision versus disagreement. Approximately 49% (n = 499) were expecting; 51% (n = 516) had a baby in the past year. Overall, 72% (n = 727) agreed to receive a product: 61% (n = 624) for RSVpreF and 60% (n = 608) for nirsevimab. RSVpreF agreement was higher among older parents (e.g., OR = 3.64; 95% CI, 1.99-6.67 for age 25-34 versus 18-24 years), those with a university degree (OR = 3.65; 95% CI, 2.01-6.64 versus high school), higher income (OR = 2.31; 95% CI, 1.01-5.28 for ≥$150k versus <$40k), or receipt/intention for Tdap (OR = 3.76; 95% CI, 2.37-5.96 versus no receipt/intention) or influenza (OR = 2.04; 95% CI, 1.29-3.21) vaccines. Agreement was higher among parents of children without a high-risk medical condition compared to those with (OR = 2.32; 95% CI, 1.44-3.72). Similar trends were observed for nirsevimab, with lower agreement also noted among those who self-researched antibodies (OR = 0.51; 95% CI, 0.30-0.88 versus not). As most respondents rated product safety (76%), effectiveness (71%), and disease severity risk (70%) as important in decision-making, providing clear information on these, alongside communications targeted to subgroups with lower agreement, may optimize uptake as programs rollout.
2026-12-31·Human Vaccines & Immunotherapeutics
Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge
Article
作者: Wang, Qiyao ; Wang, Shen ; Bao, Jianwei ; Lu, Shuangshuang ; Wu, Ke ; Xu, Long ; Mu, Ting ; Zhang, Ying ; Xie, Liang ; Ma, Tao ; Klein, Michel ; Sun, Bing
Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants, young children, and the elderly. Current licensed prefusogenic F-based RSV vaccines induce systemic immune responses through intramuscular injection. However, mucosal immunization will be required to elicit local sterilizing immunity to prevent virus replication in the nasopharynx and the lungs as well as virus shedding and transmission. Adenovirus vectors are a promising platform to develop RSV vaccines, but further evaluation of mucosal adenovirus-based prefusion F (preF) vaccines is still needed. In this study, we constructed a recombinant chimpanzee adenovirus serotype 68 vector expressing a second-generation disulfide-stabilized (DS2)trimeric preF protein (ChAd68-PreF). In mice, intranasal immunization with ChAd68-PreF induced dose-dependent increase in RSV-specific secretory IgA (sIgA) in the lower respiratory tract, demonstrating its capacity to elict mucosal immunity. Subsequently, in cotton rats, intratracheal instillation of ChAd68-PreF induced high cross-neutralizing antibody titers against RSV A and RSV B. After RSV A2 challenge, ChAd68-PreF vaccinated animals showed no detectable viral replication in the nose nor in the lungs. Moreover, ChAd68-PreF vaccination did not lead to enhanced respiratory disease (ERD) in cotton rats. These results demonstrate that mucosal delivery of ChAd68-PreF confers potent protective immunity against RSV with good safety profile, warranting further clinical development as a mucosa-targeting RSV vaccine for vulnerable populations.
2026-05-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Cost-effectiveness analysis of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for the prevention of RSV illness among infants in Hong Kong
Article
作者: Law, Amy W ; Kendall, Robyn ; Ivkovic, Luka ; Mendes, Diana ; Wong, Victoria ; Fung, Michael
OBJECTIVES:
Respiratory syncytial virus (RSV) is a leading cause of hospital admissions for acute respiratory infection among infants. A novel RSV prefusion F protein subunit (RSVpreF) vaccine has been recently approved in Hong Kong. The clinical and economic burden of RSV among infants in Hong Kong, with and without a year-round RSVpreF maternal vaccination program, was evaluated.
METHODS:
A Markov model was used to estimate clinical and economic outcomes of RSV from birth to one year of age for maternal vaccination with RSVpreF compared to no intervention. Analyses were conducted from the healthcare system perspective, with direct costs (2025 United States dollars [US$]) and outcomes discounted at 3% annually; scenario and sensitivity analyses assessed the robustness of the model.
RESULTS:
Compared to no intervention, a year-round RSVpreF vaccination program with 20% uptake would prevent 113 hospitalizations and 256 outpatient encounters annually, averting US$300,000 in direct medical costs and saving 40 quality-adjusted life years (QALYs). The incremental cost-effectiveness ratio (ICER) was US$45,776/QALY gained, falling below the threshold of 1 x gross domestic product per capita (US$56,840).
CONCLUSIONS:
Year-round RSVpreF maternal vaccination would substantially reduce RSV's clinical and economic burden among infants in Hong Kong and would be a cost-effective program.
840
项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的新闻（医药）2026-04-20
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
2026-04-14
生物医药是由生物技术产业与医药产业共同组成的现代医药领域，涵盖基因工程、细胞工程、生物医学工程及人工器官等技术方向。随着生物医药产品外包的逐渐兴起，生物医药市场开始茁壮成长。由于生物技术产品开发耗资巨大、周期漫长，使融资渠道不畅的企业面临困境，有可能在产品未能实现盈利之前，就已经被市场淘汰。在资本市场中生物医药企业除了以IPO形式上市之外，还存在反向兼并、合资、外包等多种融资形式。珠海泰诺麦博制药股份有限公司（本文简称：“泰诺麦博”或“发行人”），是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业。公司以“创造临床价值”为导向，秉持差异化创新和竞争战略，致力于全人源单抗新药的开发、制造、商业化及全球特异性血液制品的潜在替代，以满足广泛的临床需求，造福病患。泰诺麦博本次拟于上交所科创板公开发行股票不超过6,908.1928万股（不含采用超额配售选择权发行的股票数量），募资150,000.00万元主要用于新药研发项目及抗体生产基地扩建项目、补充营运资金项目。本次保荐机构为华泰联合证券，审计机构为安永华明会计师事务所。泰诺麦博作为科创板2025年7月重启“第五套上市标准”当月提交的第一家被受理的未盈利企业，于2026年4月3日通过上交所2026年第16次上市审核委员会现场审议会议通过，目前处于待提交证监会核准注册状态。泰诺麦博作为科创板第五套上市标准适用企业，显然不适合用盈利能力等传统财务指标来评价，但生物医药属于典型的“高投入、高风险、高产出、长周期”行业，这些特点造就了生物医药企业的原本脆弱性。生物医药企业固有的业务模式也可能因尚未得到市场完全验证、技术路径存在不确定性、商业化前景也可能不及预期等问题存在，也可能导致泰诺麦博仍然面临即便上市后保护期满的盈利问题。估值之家通过研究泰诺麦博本次招股书及回复交易所问询函等公开信息发现，泰诺麦博本次付费购买的行研报告数据的严谨性、客观性以及会计报表数据整体客观性是否足够均有待进一步验证。一、付费购买的行研报告数据严谨性、客观性有待进一步验证对生物医药企业而言，新药及在研管线数决定现在及未来的发展前景，发行人披露的主要产品及在研产品的进度情况，如下图所示：
从上图可见，截止招股书签署的2026年3月，发行人新药1种、在研管线数为7项，新药为已上市形成销售的代码为TNM002的斯泰度塔单抗注射液，其次为已完成临床Ⅲ期进入新药上市申请注册阶段的TNM001，其余6项管线中只两项进度略高处于临床I期状态。而据公开信息显示。截至2025年年中，20家科创板第五套标准上市公司中，19家创新药企业已上市药品品种达45个，19家科创板第五套标准上市企业的在研管线候选产品数量已达到200项以上，平均每家在研管线超过10项。而就发行人的TNM002新药及处于新药申请阶段TNM001而言，招股书中的信息显示可能并不乐观，尤其表现在发行人本次购买的行研数据上。1.斯泰度塔单抗注射液销售未及预期是否与市场真实需求不足相关发行人成立于2015年12月，发行人十年磨一剑于2025年2月拿到首款药品破伤风被动免疫制TNM002的斯泰度塔单抗注射液的新药批文，而招股书中信息显示发行人的该款新药批准后的推广及销售情况似乎并不理想。招股书中披露报告期内（下同）发行人营业收入情况，如下表所示：单位：万元
从上表可见，发行人2024年度实现技术转让主营收入1,500万元，正是因为该收入背后的协议约定导致发行人在破伤风被动免疫制剂领域新药开发受限（具体限制情况如下文所述）。2025年度自年3月开始销售斯泰度塔单抗注射液，当年实现药品销售收入5,122.49万元，如此销售成绩不但不理想，也未达发行人预期。招股书中披露的发行人首次申报的预测数与实际销售情况的比较，如下表所示：
从上表可见，发行人预计可销售27.89万瓶斯泰度塔单抗对应销售额15,608.83万元，而实际销量15.90万瓶仅实现收入5,122.49万元，预算达成率约为三分之一左右。对此发行人解释的原因为：“公司2025年3-12月斯泰度塔单抗注射液销售不及预期主要系受到多种因素的影响，除了公司原有销售预估偏高之外，其他影响因素具体包括：①未能合理预估非医保药品医院准入环节所需时间、药物当前阶段定价较高影响准入效率；②外部推广服务商等待进入医保目录契机、发力不足。”发行人对上述未达成销售预期分为内、外部两种影响因素，对此发行人表示：“2025年3-12月公司自营团队的原预期销量目标达成率为93.47%，而外部推广服务商团队的原预期销量目标达成率仅有14.97%。一方面，公司外部推广服务商团队基于对公司产品市场空间和产品优势的认可，在前期跟公司洽谈过程中展现出较强的信心与积极性，并于2025年上半年与公司达成全年超15万支销售目标……”关于发行人自营团队销售达成率93.47%，也可能已十分不易。从投入产出的角度，发行人各期重要销售费用及各期末销售人员数量情况，如下表所示：单位：万元、人
从上表可见，发行人关键销售费用各年合计分别为650.93万元、2,809.95万元、18,147.25万元，各年末的销售人员数分别为10人、172人、382人。明显可见的是发行人在尚无新药产品上市2024年度及储备了172位销售人员并开展相应的前期工作，相比上年2023年度的10位销售人员，发行人直接将销售队伍翻了17倍，到2025年度发行人再将销售队伍翻了1.22倍达到了382人。而从销售额数据来看，发行人2025年度以期末382人的销售人员及2025年度19,027.41万元的销售费用总额实现了5,122.49万元收入，销售人员人均收入额约13.41万元，显然不够上表中发行人销售费用中职工薪酬的平均额32.20万元，且发行人销售收入与销售费用支比为1:3.7。从上文可见的是，发行人披露的销售未达预期的原因均未涉及竞品及市场需求情况等，而问询函中交易所的第一个问询的“关于斯泰度塔单抗的竞争优势”问题中，即要求发行人在招股书中补充披露：进一步分析斯泰度塔单抗具有突出有效性的具体体现、安全性与HTIG相当及安全性突出的依据是否充分、是否具备可及性优势等核心问题。而引发上述问询问题的关键为发行人产品与竞品的比较，问询函中信息显示：发行人的核心产品斯泰度塔单抗试验组与试验用药品相关的AE（不良事件）和SAE（严重不良事件）分别为4.8%（21/440）和1.4%（6/440），HTIG对照组分别为3.6%（8/221）和0.9%（2/221），发行人认为斯泰度塔单抗安全性与HTIG相当、安全性突出；以及发行人斯泰度塔单抗价格为798元/瓶，TAT、F(ab’)2以及HTIG分别约为10元/瓶、25元/瓶和240元/瓶。而发行人认为主要竞品HTIG属于血液制品，产量有限，斯泰度塔单抗在可及性方面存在优势。从竞品的角度而言，发行人斯泰度塔单抗的AE（不良事件）和SAE（严重不良事件）分别为4.8%和1.4%，而竞品HTIG对照组分别为3.6%和0.9%，发行人的不良反应率高于竞品。同时发行人斯泰度塔单抗售价为798元/瓶，而三种竞品TAT、F(ab’)2以及HTIG的单价分别约为10元/瓶、25元/瓶和240元/瓶，发行人价格并不占优势明显。发行人也表示：“定价方面，公司遵循药物经济学原则，通过对公司产品和已上市同类药品的药物经济学评价研究，结合全国各级医院医护人员对公司产品的处方偏好和支付意愿，确定适宜价格，同时考虑后续医保合作和患者需求，使公司产品持续保持可及性。”基于上述不良事件率的对照，发行人认为斯泰度塔单抗安全性与HTIG相当、安全性突出，不知是否准确。而发行人产品的高价格的非优势发行人则解释竞品HTIG属于血液制品，因原材料血液采集受限所以产量有限，斯泰度塔单抗在可及性方面存在优势，但在市场规模有限下的前提下产品需求受限，则竞品HTIG的可及性也并不一定就是劣势。发行人本次上市的行业数据来自于付费的弗若斯特沙利文(下称：沙利文)报告，沙利文在该报告中认为未来我国的破伤风被动免疫制剂市场为快速增长的市场，其预测的我国破伤风被动免疫制剂市场规模（2018-2032E）情况，如下图所示：
从上图可见，弗若斯特沙利文预测认为2024年至2028年中国破伤风被动免疫制剂市场规模将以复合年增长率9.27%增长至37.9亿元，并进一步以复合年增长率13.25%增长至2032年的62.4亿元。2032年度市场规模62.4亿元为2024年度26.6亿元的2.35倍，而发行人或沙利文并未披露驱动该增长结果的驱动因素。驱动因素更多可能来源于沙利文的调研结果，招股书中信息显示：“根据弗若斯特沙利文调研，国内一线城市及三线城市医院专家访谈结果显示国内临床外伤患者中平均超过50%需要使用破伤风被动免疫制剂，中国破伤风被动免疫制剂使用人群规模由2018年的1,963.0万人以复合年增长率8.34%增长至2024年的3,174.0万人。预计2024年至2028年中国破伤风被动免疫制剂使用人群规模将以复合年增长率8.03%增长至4,323.6万人，并进一步以复合年增长率5.21%增长至2032年的5,297.2万人。破伤风被动免疫制剂使用人群增长受到社会活动活跃程度、城乡经济发展建设、破伤风防治教育普及等因素共同驱动。”若沙利文若以此调研结果作为国内市场规模的预测依据，则预测结果的客观性及准确性可能难免存疑。发行人核心产品斯泰度塔单抗是一种破伤风单抗，属于破伤风被动免疫制剂，用于外伤暴露后破伤风的紧急预防，破伤风的预防机制分为主动与被动两种免疫模式，主动预防模式下以接种破伤风疫苗实现。尤其是我国大规模实现儿童免疫接种后，通过主动免疫模式获得防护的人群比例逐年上升，其对发行人推出的被动免疫模式下斯泰度塔单抗制剂的需求形成反向抵消作用。招股书中显示国家卫健委规范了非新生儿外伤后破伤风疫苗和被动免疫制剂的使用原则，对于不同免疫接种史的患者，不同风险等级下，建议采取不同的破伤风疫苗与被动免疫制剂预防方案，具体如下表所示：
从上表可见，对于接种超过3剂破伤风疫苗的，其对被动免疫制剂的需求几乎为0，上表中仅存在最后一行“小于3剂或免疫史不详”且满足未在6小时内进行医疗处理；伤口接触泥土、人或动物粪便及哺乳动物唾液等污染物；穿刺伤；撕脱伤；挤压伤；火器伤；烧烫伤及冻伤；存在未去除的缺血或坏死组织；伤口内有未去除的异物；已有感染征象伤口等高风险下才需要破伤风被动免疫制剂。因此发行人的破伤风被动免疫制剂必要场景可能相当严格或苛刻，甚至可以将上述相对严苛的使用条件定义为意外，而意外很难被量化及精确统计预计几乎是常识，那么沙利文对国内市场规模的预测如果以意外为主的话，其预测数据的客观性也有待进一步验证。与上述国内破伤风被动免疫制剂市场规模预测相对的是，沙利文对欧美破伤风被动免疫制剂市场规模的预测，则明显不如上述国内市场规模的激进，其预测的欧美破伤风被动免疫制剂市场规模（2018-2032E）如下图所示：
从上图可见，欧美破伤风被动免疫制剂市场于2024年达到33.7亿美元，沙利文预计到2032年市场规模反而会下降至32.4亿美元，其认为的主要原因为由于欧美破伤风免疫模式成熟，被动免疫制剂市场规模稳定。当然沙利文仍然预计2028至2032年欧美破伤风特异性抗体药物市场规模将以复合年增长率75.56%增长至2.7亿美元。接上文所述，发行人2024年度产生技术转让主营收入1,500万元，源于其向百克生物转让相关技术。发行人披露：“根据公司与百克生物签署的《全人源抗破伤风毒素单克隆抗体技术转让合同》相关约定，除甲方（百克生物）选择的转让抗体之外其余TT 抗体，乙方（泰诺麦博）保留另外2 个抗体的全球开发权限，任何一方在开发区域内都可以进行再次转让。双方共同约定，无论上市产品为单价或双价，限定各方最多开发一个药品上市。在此协议框架下，为避免过度竞争，全球最多只有两个破伤风毒素抗体产品上市。乙方不再开发其他的全人源破伤风毒素抗体项目……”此自缚手脚的做法直接导致发行人：“在破伤风抗体开发上市的个数约定方面，鉴于公司已有斯泰度塔单抗注射液（即前述协议约定中的“TT0069”）获批上市，未来公司将遵守前述协议约定，不再基于其他候选破伤风抗体分子进行相关研发活动以保证公司始终仅开发一款破伤风预防用药品上市，但公司仍将基于斯泰度塔单抗注射液进行其他研究。”2.抗呼吸道合胞病毒RSV单抗Ⅲ期临床试验是否真实可靠发行人的另一款核心产品TNM001（抗呼吸道合胞病毒RSV单抗）以高危及非高危婴儿为适应症人群已于2026年2月递交NDA并获受理，注册分类为创新型生物药（治疗用生物制品1类），同时已纳入优先审评程序，目前处于CDE审评过程中，尚未在中国境内获得药品注册批准。理论上发行人获得新药批文可能只是时间问题，但从临床试验的角度尤其是Ⅲ期临床来看，发行人研发出这款新药的过程却可能相当蹊跷。根据招股书中披露的信息显示，该药物的Ⅲ期临床分为301与302两个项目展开，相关临床信息部分如下：“TNM001-301（III期部分）：面向1岁以下的非高危婴儿。该临床试验是一项在中国开展的随机、双盲、安慰剂对照和平行组设计的Ⅲ期临床试验，旨在评估TNM001在健康足月儿和晚期早产儿（即非高危婴儿）中预防RSV下呼吸道感染（LRTI）的有效性、安全性和免疫原性。该临床试验的主要入选标准：①1岁以内的健康晚期早产儿（35周0天≤胎龄<37周0天）或足月儿（胎龄≥37周0天），患有基础疾病（如唐氏综合征和唇裂）但无其他风险因素的婴儿允许参加试验，性别不限……③受试者的法定监护人（父亲或母亲或其他法定监护人）已签署知情同意书（ICF）。TNM001-302：面向1岁以下的高危婴儿。该临床试验是一项在中国开展的随机、双盲、安慰剂对照和平行组设计的III期临床研究，旨在评估TNM001在高危婴儿人群中预防RSVLRTI的有效性、安全性和免疫原性。该临床试验的主要入选标准：①1岁以内的早产儿（胎龄﹤35周0天）、CHD和/或早产儿CLD患儿，性别不限……③受试者的法定监护人（父亲或母亲或其他法定监护人）已签署知情同意书（ICF）。”从上述信息可知，该两项试验的受试对象均为1岁以内的健康晚期早产儿，301试验需1岁以内的健康晚期早产儿但患有基础疾病，302试验则不需要。且婴儿受试者的法定监护人签署同意书……关于招募受试婴儿人数情况，招股书中发行人也有披露：“TNM001-301试验的第二部分（III期试验）共计划招募1,500例受试者，其中，TNM001组1,000例，安慰剂组500例。该试验实际共入组1,501例受试者。TNM001-302试验共计划招募309例受试者，其中，TNM001组206例，安慰剂组103例。该试验实际共入组307例受试者。”上述301、302两项III期临床试验方案的部分具体情况对比，如下图所示：
从上图可见，发行人分别于2024年10月及11月完成1,501例、307例0-1岁婴儿受试者入组实验，并于后继顺利完成相关Ⅲ期临床实验。而婴儿因为免疫系统尚未发育完善，作为受试对象用于药物试验风险比儿童更高。因婴儿临床试验涉及高度脆弱的人群，因此其医学试验的伦理学原理必须严格遵循国际通行的医学伦理准则，对其伦理审查与机构要求也极高，并需结合儿童特殊生理、心理及法律地位进行特殊保护。虽然我国目前尚未出台专门针对“婴儿”（0–1岁）的独立伦理法规，但儿科临床试验技术指导原则已明确涵盖新生儿及婴幼儿阶段。针对婴幼儿RSV疫苗国际方面招股书中信息显示：“在RSV感染预防领域，高危感染风险患儿仍存在未被满足的针对RSV具备特异性的预防及治疗药物的临床需求。全球婴幼儿RSV疫苗研发经过了60余年的坎坷历程仍未取得明显的成果，随着美国FDA在2024年叫停了Moderna的两款mRNARSV疫苗针对婴儿的临床试验，截至目前全球范围内尚无完整覆盖0-2岁婴幼儿的上市或临床在研RSV疫苗。”从上述国际端看，美国FDA在2024年叫停了两款针对婴儿的临床试验，且行业内已经经历60余年的坎坷历程仍未取得明显的成果，是否都出于婴儿医学实验的伦理性考虑未知。但婴幼儿作为社会构成基本单元的家庭的核心资产，从一般伦理学的角度可知婴幼儿的父母不会将亲生婴幼儿子女作为医学实验的受试者，尤其是对健康的婴幼儿而言。即便是有的婴幼儿父母存在相反现象，但无论其婴幼儿父母及实验本身也同样面临基本伦理学的巨大考验。从此角度来看，发行人本次针对0-1岁婴幼儿的RSV疫苗Ⅲ期临床试验完成的真实性可能存疑。另一方面发行人回复函中披露的发行人主要研发服务供应商的采购价格确定依据中，关于受试者招募的服务商有两家，具体如下表所示：
从上表可见，该两家负责受试婴儿招募的服务商分别为上海中毅医药科技发展有限责任公司及上海快募医药信息科技有限公司。首先，儿童临床试验伦理审查与机构所要求试验机构资质要求：必须在国家药品监督管理局（原CFDA）认证的儿科人群药物临床试验机构进行。该两家服务商作为领床实验的组织方而非直接承办方存在，让发行人的该两项临床试验产生了信息披露的隔离。其次，天眼查平台信息显示，上海中毅医药科技发展有限责任公司成立于2019年03月，最近三年缴纳社保人数分别为11、13、21人，而上海快募医药信息科技有限公司成立于2020年10月，实收资本仅60万元，最近三年缴纳社保人数分别为32、47、5人。该两家服务商能否真实完成发行人所需的RSV疫苗Ⅲ期临床试验的受试者招募任务，可能同样真实性有待进一步验证。竞品方面，发行人披露：RSV单抗已上市产品和在研管线在适应症人群和给药方式方面等存在差异情况，如下表所示：
从上表可见，全球范围已上市竞品包括阿斯利康制药的帕利珠单抗、阿斯利康制药和赛诺菲制药联合开发的尼塞韦单抗、默沙东制药的Clesrovimab以及辉瑞的妊娠女性RSV疫苗Abrysvo（RSV-preF），在研药物中还包括位于NDA阶段的瑞阳（山东）生物制药有限公司的RB0026等。此外据公开信息显示：“目前针对RSV感染，国内专家也在开展相关药物研发和临床研究工作，如中国科学院分子细胞科学卓越创新中心（生物化学与细胞生物学研究所)研究组组长孙兵教授正牵头开展一项单抗药物的临床研究。”尼塞韦单抗（Nirsevimab，Beyfortus®）分别于2022年、2023年获得欧盟EMA与美国FDA批准，用于预防早产儿和幼龄婴儿的RSV感染，并于2023年12月在国内上市，系全球第一款用于预防RSV感染的长效单克隆抗体；2025年6月，默沙东研发的Clesrovimab（Enflonsia®）在美国获批上市，成为全球第二款用于预防RSV感染的长效单克隆抗体，目前在中国提交NDA申请并获受理。招股书中披露的主要竞品的临床试验数据情况如下：“尼塞韦单抗针对高危婴儿的II/III期临床试验（即序号05试验）和Clesrovimab针对高危婴儿的III期临床试验（即编号MK-1654-007试验）均以Palivizumab为对照药。但由于前述尼塞韦单抗及Clesrovimab在高危婴儿人群中开展的临床试验缺少Palivizumab预防需就医的RSVLRTI方面的有效性数据，无法确定非劣效试验的界值，导致无法以有效性为主要终点，只能以安全性为主要终点。考虑到高危人群与健康足月儿/晚期早产儿在RSV感染的发病机制、药物药理学特征以及预期治疗反应等方面的相似性，尼塞韦单抗和Clesrovimab均采用儿科外推的方法，即通过上述两个人群在给药后相似的药物暴露量，将健康足月儿和晚期早产儿中经确证的有效性外推至高危婴儿人群，并获得了全球主要药监机构的上市批准。”从上述信息不难看出，上述竞品上市时间均表现出较晚的状态，且主要竞品中也面临临床数据不完整问题，尤其是缺少高危婴儿人群临床试验数据而采用儿科外推的方法进行推断，且上表中的国内瑞阳生物处于NDA阶段的RB0026也存在适用范围不包括高危婴儿的问题，但对发行人而言这些问题都似乎是不存在的，发行人的过人之处也可能并不一般。与上文破伤风被动免疫制剂市场规模预测问题相同的是，本次招股书中沙利文报告同样将中国0-1岁婴儿呼吸道合胞病毒预防被动免疫制剂市场规模预测为增量市场，且增长比例同样不低。招股书中披露的沙利文预测的中国0-1岁婴儿呼吸道合胞病毒预防被动免疫制剂市场规模（2018-2032E）情况，如下图所示：
从上图可见，根据沙利文报告，预计2024年至2028年中国0-1岁婴儿呼吸道合胞病毒预防被动免疫制剂市场规模将以复合年增长率70.3%增长至24.8亿元，并进一步以复合年增长率3.7%增长至2032年的58.0亿元。沙利文上述预测结果是否基于其“随着未来逐渐丰富的可选单抗种类增加、RSV预防意识的提升以及婴幼儿群体用药渗透率的增长，RSV被动免疫制剂市场在未来将会逐渐扩大”不得而知。但在任何一个国家，随着婴儿出生率的下降，任何于婴儿有关的行业所在的市场规模预计大幅增长，其前提本身的严谨性就值得商榷。而在欧美市场规模的预测上，沙利文又一次表现出保守的情况：“根据弗若斯特沙利文报告，2024年欧美0-1岁婴儿呼吸道合胞病毒被动免疫制剂市场规模达到17.9亿美元，预计2024年至2028年欧美0-1岁婴儿呼吸道合胞病毒预防被动免疫制剂市场规模将以复合年增长率12.43%增长至28.5亿美元，2019-2032E以复合年增长率10.13%进一步增长至2032年的42.0亿美元。”二、会计报表数据整体客观性是否足够有待进一步验证就本次IPO而言，更能反映发行人招股书质量的是发行人财务数据的客观性，而从发行人会计数据的角度，发行人本次财务数据的客观性可能存疑。以核心的财务指标为例，招股书中发行人披露的合并资产负债率依次为28.19%、58.96%、88.18%，发行人资产负债率的对齐颗粒度相当精确几乎为整30%，即依次每年以30%的递增变化。资产负债率指标作为统驭性财务指标，虽然表面上反映资产负债表中的数据关系，但资产负债表综合反映利润表及现金流量表数据结果，发行人资产负债率数据的规律性变化，从一定程度上可能说明发行人本次会计报表的整体客观性不足，具体体现在报表级数据规律上。本次会计报表中发行人存在一级科目数据规律性变化情况，如下表所示：单位：万元
从上表可见，就利润表而言，除营业收入及成本外发行人出现6项数据规律性变化，三大期间费用中除增长明显的销售费用外，出现了管理费用及研发费用两大期间费用数据规律性变化，甚至负数的营业利润也出现了数据规律性变化。就资产负债表而言，如上文所述在资产负债率财务指标数据的规律性变化下，共出现13项数据规律性变化，占本次总规律性变化数据的比例约为57%，且较具代表性，如货币资金、存货、固定资产、长期借款及负债合计等数据，而此类数据与企业实力、盈利能力及融资能力相关。就现金流量表而言，发行人出现4项数据规律性变化，其中经营活动现金流入小计数据规律性变化反映发行人对经营活动现金流的干预结果，筹资活动产生的现金流量净额规律性变化与上述融资能力相关相对应，而期末现金及现金等价物余额的规律性变化与则上述发行人表现的企业相对实力有关。考虑到发行人尚未盈利因而不适合用盈利能力等传统财务指标评价，本次发行人会计报表中即出现23项一级会计科目数据规律性变化，从某种意义上说，发行人本次上市的财务数据整体客观性有待进一步验证。如果上表数据规律性变化不够直观，我们采用取大数分析法进行简化，并按规律类型重新排序，结果如下表所示：
从上表可见，所涉23项数据呈三类规律性变化：第一类为等额递增规律变化：具体为上表中第1-5行以自然数增加变化，第6-7行以数字2、第8-9行以数字3、第10行以数字6等额增加规律变化。第二类为等额递减规律变化：具体为上表中第11-12行以自然数减少变化，第13行以数字2、第14行以数字3、第15行以数字4等额递减规律变化。第三类为以等额变化数但不依次出现的隐蔽规律变化：具体为上表中第16-19行以自然数但不依次出现变化，第20-21行以数字3、第22-23行以数字4为间隔数但不依次出现规律变化。虽然第三类数据规律性变化不如前两类明显，但存在普遍性以及对研究数组内数据分布规律具重要显现作用而加以应用。三、结语综上诉述：泰诺麦博作为一家生物药企，本次携一款销售未达预期的上市新药破伤风被动免疫制剂以及另一款处于NDA阶段的重组抗呼吸道合胞病毒全人源单克隆抗体管线申请科创板上市。另一方面我国生物医药的原创性研究及资本市场落后于发达国家，导致我国的生物医药产业陷入低水平重复生产和恶性竞争的局面。另一方面发行人于招股书表示于2029年能够实现盈利，其未来面临的盈利压力可能并不小。就市场方面而言，发行人新上市药破伤风被动免疫制剂斯泰度塔单抗，在提前储备172位销售人员的情况下当年销售不及预期，发行人归因为外部推广服务商团队的发力不足，但是否可能源于其对市场需求或规模的估计过于乐观，其引用的市场数据来自于付费的弗若斯特沙利文报告，而弗若斯特沙利文对国内破伤风被动免疫制剂市场规模增长速度过快，而对欧美相关市场预测却相对保守，表明本次引用的弗若斯特沙利文报告中数据的严谨性、客观性有待进一步验证。就产品方面而言，发行人抗呼吸道合胞病毒RSV单抗临床试验面向1岁以下的高危和非高危婴儿，其于国内完成Ⅲ期临床试验，其临床试验完成也面临巨大的伦理学考验，而从美国叫停相关临床实验以及国内、外均无高危婴儿的试验数据来看，发行人第二款新药可能面临关键临床试验是否真实可靠问题。当然弗若斯特沙利文报告中对该药未来市场的预测仍为高速增长，也同样难免预测数据的严谨性存疑。从财务方面而言，发行人在资产负债率对齐颗粒度相当精确情况下，至少出现23项报表级数据规律性变化，说明本次上市的财务数据整体客观性有待进一步验证。
2026-04-08
Infectious Diseases and Therapy Volume 15, Issue 1
感染性疾病与治疗 15卷 1期
https://link.springer.com/journal/40121/volumes-and-issues/15-1
Review（综述）
1
How to Better Screen for Blood-Borne Viruses, Specifically HIV, in Hospital Emergency Departments: French and European Perspectives
医院急诊科如何更好地筛查血源性病毒（尤其是HIV）：法国和欧洲视角
Anthony Romain ChauvinBruno George SpireOlivier Bouchaud
Pages: 1 - 18
2
Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review
了解新冠疫情后百日咳爆发的流行病学及影响因素：叙述性综述
Juan C. Vargas-ZambranoSorin AbrudanDenis Macina
Pages: 19 - 41
Part of 1 collection: Digital Features - Infectious Diseases
所属专题集：数字专题 - 传染病
3
The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review
康替唑胺抗结核的结构、特性及临床应用价值：叙述性综述
Tao ChenWeili LiFan Wu
Pages: 43 - 56
4
A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome
综述：多西环素暴露后预防用药及其对抗菌药物耐药性和人体微生物组的影响
Ruben Fernandez-IbanezSantiago MorenoMoises Fernandez
Pages: 57 - 84
Original Research（论著）
5
Clinical Impact of Implementing a Specific Clinical Pathway for the Management of Clostridioides difficile Infection
实施特定临床方法治疗艰难梭菌感染的临床影响
Miguel Rodríguez-FernándezRocio HerreroNicolás Merchante
Pages: 85 - 100
6
Intensive Care Unit Stay and Mechanical Ventilation Among Adults with Respiratory Syncytial Virus-Related Hospitalization by Age and Comorbidity Status
按年龄和合并症状况划分的呼吸道合胞病毒相关住院成人患者的重症监护病房住院时间和机械通气情况
Caihua LiangYun ZhouElizabeth Begier
Pages: 101 - 115
7
Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care
医疗保险覆盖的HIV感染者治疗坚持情况、用药转换情况及护理缺口
Suying LiUche MordiPhyllis C. Tien
Pages: 117 - 132
8
High-Dose Minocycline Improves Outcomes in Acinetobacter baumannii Group Pneumonia: A Propensity-Weighted Cohort Study with MIC-Based Insights for Breakpoint Revision
大剂量米诺环素可改善鲍曼不动杆菌群肺炎的预后：一项基于倾向加权队列的研究，并基于最低抑菌浓度提出折点修订见解
Yu-Tao TsengYang-Chuan ChenYung-Chih Wang
Pages: 133 - 148
9
Post-cranial Neurosurgery Cutibacterium acnes Infections: Clinical Correlates, Presentation, and Outcomes—A Matched Case–Case–Control Study
颅脑神经外科术后皮肤杆菌属感染：临床相关性、表现及预后——一项匹配病例-病例-对照研究
Neta ShirinOfek ArvivIli Margalit
Pages: 149 - 164
10
Bone Mineral Density Changes in People with HIV Who had Immediate Switch Versus Deferred Switch from Tenofovir Disoproxil Fumarate-Based Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Multicenter, Open-Label, Randomized Clinical Trial
从基于富马酸替诺福韦二吡呋酯的方案立即转换与延迟转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者骨密度变化：一项多中心、开放标签、随机临床试验
Yueming ShaoXinping YangJun Chen
Pages: 165 - 181
11
Microbiological, Clinical, and Pharmacokinetic/Pharmacodynamic Data to Support EUCAST Aztreonam–Avibactam Minimum Inhibitory Concentration Susceptibility Breakpoints Against Enterobacterales
支持欧洲抗微生物药物敏感性试验委员会（EUCAST）针对肠杆菌科细菌的氨曲南-阿维巴坦最低抑菌浓度敏感性折点的微生物学、临床及药代动力学/药效学数据
Susan R. RaberRujia XieJoseph W. Chow
Pages: 183 - 195
12
Epidemiology of Invasive Escherichia coli Disease in Adults Using Routine Healthcare Records from the United States, 2002–2022
利用美国常规医疗记录（2002-2022年）分析成人侵袭性大肠杆菌病的流行病学特征
Mark A. SchmidtMaxim BlumJeroen Geurtsen
Pages: 197 - 216
13
Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies
转换为比克替拉韦/恩曲他滨/丙酚替诺福韦的HIV感染者生活质量及治疗满意度：观察性队列研究的汇总分析
Andrea AntinoriYoshiyuki YokomakuMarta Boffito
Pages: 217 - 244
14
Dual Transmission Dynamics of Carbapenem Resistance in Pediatric Oncology: Plasmid-Mediated and Clonal Spread of blaNDM-5 Enterobacterales
儿科肿瘤中碳青霉烯类耐药性的双重传播动态：blaNDM-5肠杆菌科的质粒介导与克隆传播
Deena JalalMaryam LotfiLobna Shalaby
Pages: 245 - 263
Part of 1 collection:Digital Features - Infectious Diseases
所属专题集：数字专题 - 传染病
15
Cost-Effectiveness Analysis of Aztreonam–Avibactam Compared with Colistin Plus Meropenem in Treating Metallo-Beta-Lactamase-Producing Enterobacterales Infections in Spain
氨曲南-阿维巴坦与黏菌素联合美罗培南治疗西班牙产金属β-内酰胺酶肠杆菌科感染的成本效果分析
Gerardo AguilarPatricia Ruiz-GarbajosaJulián Torre-Cisneros
Pages: 265 - 284
16
Synchronous anal HPV Infection in Patients with HPV-Related Gynaecological Diseases: A Prospective Study
人乳头瘤病毒（HPV）相关妇科疾病患者同步肛部HPV感染：一项前瞻性研究
Michał BrzezińskiMaciej Stukan
Pages: 285 - 295
17
Growth in Anaerobic Bottles is an Independent Predictor of Mortality in Pseudomonas aeruginosa Bloodstream Infections
厌氧瓶中生长是铜绿假单胞菌血流感染死亡的独立预测因素
Daniel N. MarcoLaura MorataAlex Soriano
Pages: 297 - 311
18
Acute and Long-Term Healthcare Utilization and Expenditures for Serious Bacterial Infections among Newborns in US Hospitals
美国医院新生儿严重细菌感染的急性和长期医疗资源利用及费用
Kristen N. NobleKatharina SchleyDerek Weycker
Pages: 313 - 325
19
Impact of Risk Stacking on COVID-19–Related Healthcare Utilization: A Real-World Retrospective Cohort Study
风险叠加对新冠相关医疗资源利用的影响：一项现实回顾性队列研究
Frank R. ErnstLeah McGrathAlejandro Cané
Pages: 327 - 343
20
Chest Computed Tomography Patterns Associated with Severity in Adults with Respiratory Syncytial Virus Infection: A Retrospective Cohort Study
成人呼吸道合胞病毒感染严重程度相关的胸部计算机断层扫描模式：一项回顾性队列研究
Marie Le GoffYoussef ZaarourNicolas de Prost
Pages: 345 - 363
Case Series（病例系列）
21
Management and Resolution of Hypersensitivity Pneumonitis-Related Events in Japanese Patients Treated with Amikacin Liposome Inhalation Suspension in the CONVERT and INS-312 Clinical Trials
在CONVERT和INS-312临床试验中，接受硫酸阿米卡星脂质体吸入混悬液治疗的日本患者发生过敏性肺炎相关事件的管理与解决
Yoshitaka YamazakiTaku NakagawaNaoki Hasegawa
Pages: 365 - 379
Letter（读者来信）
22
A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis”
对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复
Pavo MarijicJulian WitteChristiane Hermann
Pages: 381 - 383
23
Letter to the Editor Regarding“The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis”
致编辑的信：关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”
Kuan-Fu LiaoShih-Wei Lai
Pages: 385 - 386
Correction（更正）
24
Correction: Budget Impact Analysis of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) for Recurrent Clostridioides difficile Infection in the United States
更正：美国复发性艰难梭菌感染粪便微生物群孢子活菌brpk（原SER-109）的预算影响分析
Michele WilsonYoav GolanAlpesh N. Amin
Pages: 387 - 387
25
Correction: A Response to: Letter to the Editor Regarding “The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis”
更正：对《关于“抑郁障碍患者带状疱疹风险：一项德国索赔数据库分析”的来信》的回复
Pavo MarijicJulian WitteChristiane Hermann
Pages: 389 – 389
Infectious Diseases and Therapy Volume 15, Issue 2
感染性疾病与治疗 15卷 2期
https://link.springer.com/journal/40121/volumes-and-issues/15-2
Review（综述）
1
HepatitisA to E in People with HIV: A Virus-Specific Review of Prevention and Treatment
HIV感染者中的甲型至戊型肝炎：针对不同病毒的预防和治疗综述
Kuan-Yin LinYi-Chia HuangChien-Ching Hung
Pages: 391 - 415
2
The Cefazolin Inoculum Effect: An Underappreciated Factor in MSSA Treatment Strategies
头孢唑林接种物效应：甲氧西林敏感金黄色葡萄球菌治疗策略中一个未被充分重视的因素
Prakhar SrivastavaElizabeth SingletonRazieh Kebriaei
Pages: 417 - 441
3
Meningococcal Disease in Older Adults: Challenges in Diagnosis and Management
老年人群中的脑膜炎球菌病：诊断与治疗的挑战
Muhamed-Kheir TahaCatherine Weil-OlivierSaber Yezli
Pages: 443 - 459
4
The Future of Antibiotics and Artificial Intelligence: Some Thoughts from Discovery to Bedside
抗生素与人工智能的未来：从发现到临床应用的一些思考
Daniele Roberto GiacobbeAlessandra Agnese GrossiCesar de la Fuente-Nunez
Pages: 461 - 475
Original Research（论著）
5
Estimating the Health and Economic Burden of Pneumococcal Diseases Attributable to PCV21 Versus PCV20 or PPSV23 Serotypes Among Adults in Norway
挪威成年人中PCV21与PCV20或PPSV23血清型所致肺炎球菌疾病的健康和经济负担估算
Zinan YiAthar Ali TajikKwame Owusu-Edusei
Pages: 477 - 490
6
Seven versus Fourteen Days of Antibiotics for Gram-Negative Bacteremia from a Urinary Tract Source: a Systematic Review and Meta-analysis
尿路感染来源的革兰阴性菌血症抗生素治疗7天与14天的系统综述和荟萃分析
Graciela LunaAndrea RodriguezMichael Sabina
Pages: 491 - 505
7
Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Healthcare-Associated Bloodstream Infections in Brazil: Results from A Prospective Countrywide Multicenter Study
巴西医疗保健相关血流感染中耐甲氧西林金黄色葡萄球菌的分子流行病学：一项前瞻性全国多中心研究的结果
Laura C. AntochevisLetícia O. SudbrackAlexandre P. Zavascki
Pages: 507 - 525
8
Long-Term Antibody Persistence After Hepatitis A Vaccination in Healthy Toddlers: Insights from Modeling
健康幼儿接种甲型肝炎疫苗后长期抗体持久性：基于模型的见解
Carlos EspulHéctor Horacio CuelloLaurent Coudeville
Pages: 527 - 538
9
Prevalence of Respiratory Syncytial Virus in Adult Patients with Respiratory Illnesses in Low to Middle-Income Countries: A Systematic Review and Meta-Analyses
中低收入国家成人呼吸道疾病患者中呼吸道合胞病毒的流行率：一项系统综述和荟萃分析
Digant GuptaAmandeep KaurAdriana Guzman-Holst
Pages: 539 - 559
10
Novel Diagnostic Marker Interleukin-33 for Invasive Pulmonary Aspergillosis in Acute-on-Chronic Liver Failure: A Proof-of-Concept Prospective Study
慢加急性肝衰竭合并侵袭性肺曲霉病的新型诊断标志物白细胞介素-33：一项概念验证前瞻性研究
Lanyue HuangMeng ZhangQin Ning
Pages: 561 - 576
11
Testing the Feasibility of a Self-Help Intervention That Includes Lymphatic Drainage to Reduce Fatigue-Related Symptoms Among Patients with Long COVID in General Practice: Experiences from Our Randomized Controlled Trial (RCT)
在全科医疗中测试包含淋巴引流以减轻长期新冠患者疲劳相关症状的自助干预措施的可行性：我们的随机对照试验（RCT）经验
Lisa RisteRaymond PerrinAdrian Heald
Pages: 577 - 589
12
Comparative Diagnostic Performance of the 36-Minute STANDARD M10 Fast Assay for Molecular Diagnosis of SARS-CoV-2, InfluenzaA and B, and Respiratory Syncytial Virus in Near-Patient Settings
36分钟STANDARD M10快速检测法在床旁检测中对SARS-CoV-2、甲型和乙型流感病毒以及呼吸道合胞病毒的分子诊断性能比较
Alexander DomnichGiada GarzilloGiancarlo Icardi
Pages: 591 - 604
13
Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study
感染奥密克戎的危重症COVID-19患者的临床表型：一项全国性前瞻性队列研究
Etienne AudureauPierre Baythe SEVARVIR investigators
Pages: 605 - 628
Brief Report（简报）
14
How do Recent Population-Level RSVpreF Vaccine-Impact Results from the United Kingdom Relate to Previously Reported Vaccine Effectiveness Results?
英国最近公布的RSVpreF疫苗在人群层面的影响结果与之前报告的疫苗有效性结果有何关联？
Negar AliabadiQing LiuElizabeth Begier
Pages: 629 - 637
Case Report（病例报告）
15
Continuous Infusion of Aztreonam–Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae
针对OXA-48和NDM-1共产生的ST147型肺炎克雷伯菌感染，采用高负荷剂量后持续输注氨曲南-阿维巴坦
Paul Laffont-LozesFanny VillaRomaric Larcher
Pages: 639 - 649
Infectious Diseases and Therapy Volume 15, Issue 3
感染性疾病与治疗 15卷3期
https://link.springer.com/journal/40121/volumes-and-issues/15-3
Commentary（述评）
1
Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease
预防婴儿呼吸道合胞病毒疾病中孕妇接种疫苗的全面健康及社会价值的分类学研究
J. P. SevillaDaria BurnesDavid E. Bloom
Pages: 651 - 682
Original Research（论著）
2
Characteristics of Haemophilus influenzae Isolates Responsible for Invasive Infections in Poland in 2018–2023
2018-2023年波兰引起侵袭性感染的流感嗜血杆菌分离株的特征
Marlena KiedrowskaKinga BłaszczykAnna Skoczyńska
Pages: 683 - 700
3
Evaluating the Effectiveness of 2024–2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged ≥ 18 years in the United States: An Observational Matched Cohort Study
评估2024-2025年季节性mRNA-1273疫苗对美国≥18岁成年人预防与COVID-19相关住院和就医的效力：一项观察性匹配队列研究
Nevena VicicAlina BogdanovAmanda Wilson
Pages: 701 - 714
4
Elevated Plasma GDF-15 Levels Are Associated with Aging, Multimorbidity, and Tobacco Exposure in People with HIV
HIV感染者中血浆GDF-15水平升高与衰老、多种合并症及烟草暴露相关
Aida López LópezJacobo Alonso DomínguezCoRIS Cohort
Pages: 715 - 731
5
High Burden of Febrile Sub-microscopic Plasmodium Mixed Infections in Central India: A Cross-Sectional Study
印度中部无症状疟原虫混合感染伴发热疾病负担高：一项横断面研究
Nimita DeoraVeena PandeAbhinav Sinha
Pages: 733 - 747
6
How Status Quo Bias Shapes Willingness, Uptake, and Adherence to PrEP Among Chinese MSM: A Behavioral Economics Perspective
从行为经济学视角看现状偏见如何影响中国男男性行为者对暴露前预防的意愿、接受度和依从性
Min ZhaoXiang ZhaoLei Zhang
Pages: 749 - 767
7
Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged≥56 Years: A Phase III, Open-Label Study
四价脑膜炎球菌结合疫苗（MenACYW-TT）在≥56岁潜在朝觐/副朝觐者中的免疫原性和安全性：一项III期、开放标签研究
Ghassan S. DbaiboIsmail BalikMehmet Ceyhan
Pages: 769 - 785
Part of 1 collection: Digital Features - Infectious Diseases
所属合集：数字专题 -传染病
8
Clinical Impact of Droplet Digital PCR-Guided Antibiotic Stewardship on Prognosis in Patients with Suspected Bloodstream Infection: A Prospective Observational Study
液滴数字PCR指导的抗生素管理对患者疑似血流感染预后的临床影响：一项前瞻性观察研究
Ziqiang ShaoJingwen ZhuBangchuan Hu
Pages: 787 - 807
9
Outpatient RSV Testing Rates Among US Adults with Lower Respiratory Tract Disease, 2017–2024
2017-2024年美国下呼吸道疾病成人患者门诊呼吸道合胞病毒检测率
Katherine K. PerezKashmira DateElizabeth Begier
Pages: 809 - 834
10
Role of Cefiderocol in the Treatment of Carbapenem-Resistant Nonfermenting Gram-Negative Bacilli (Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia) Infections: An Expert Statement
头孢地尔在治疗碳青霉烯类耐药非发酵革兰氏阴性杆菌（鲍曼不动杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌）感染中的作用：专家声明
Alexandre BleibtreuYoussef BennisCoRIS Cohort
Pages: 835 - 857
11
IgG4 Neutralization and Sustained Total IgG Fc-Effector Functions Following Repeated SARS-CoV-2 Vaccination with mRNA-1273
重复接种mRNA-1273疫苗后IgG4中和作用及总IgG Fc效应功能的持续存在
Paulina KaplonekHarry BerteraCarole Henry
Pages: 859 - 874
12
Rising Burden of Herpes Zoster among General Adults and Increased-Risk Groups in Eastern China, 2015–2021: A Population-Based Cohort Study
2015-2021年中国东部普通成人及高风险人群带状疱疹负担上升：一项基于人群的队列研究
Zhenwei LiShenjia GuChuanxi Fu
Pages: 875 - 888
13
Safety and Efficacy of Fecal Microbiota, Live-jslm for Prevention of Recurrent Clostridioides difficile Infection Among Hospitalized Participants in PUNCH CD3-OLS
PUNCH CD3-OLS研究中住院患者使用活菌粪便微生物群（Live-jslm）预防复发性艰难梭菌感染的安全性和有效性
Andrew M. SkinnerThomas P. LodiseJordan E. Axelrad
Pages: 889 - 901
Letter（读者来信）
14
Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States”
致编辑的信：关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件”
Keiji Konishi
Pages: 903 - 905
15
A Response to: Letter to the Editor Regarding “Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States”
回复：致编辑的信——关于“美国HIV和乙型肝炎病毒合并感染者启动抗逆转录病毒治疗后发生晚期肝病事件”
Ching-Yi ChuoWoodie ZachryLi Tao
Pages: 907 - 909
16
A Response to: “Letter to the Editor regarding ‘Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study'”
回复：致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究”
Romain ArrestierKeyvan Razazi
Pages: 911 - 914
17
Letter to the Editor regarding 'Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study'
致编辑的信——关于“聚丙烯腈衍生滤器连续性肾脏替代治疗对卡泊芬净浓度的影响：一项回顾性研究”
Julien MassolValentin MauletFrédéric J. Baud
Pages: 915 - 919
Infectious Diseases and Therapy Volume 15, Issue 4
感染性疾病与治疗 15卷 4期
https://link.springer.com/journal/40121/volumes-and-issues/15-4
Review（综述）
1
Outpatient Parenteral Antimicrobial Therapy (OPAT) in Italy: A Scoping Review
意大利门诊静脉注射抗菌药物治疗（OPAT）：一项范围综述
Chiara MorealSimone GiulianoCarlo Tascini
Pages: 921 - 939
2
Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration—A Review
重新构想噬菌体疗法治疗多重耐药病原体：从生物银行到卫生系统整合——综述
Abay A. AyeleWenfeng LiuAbel A. Negash
Pages: 941 - 957
3
Navigating the Viral Hepatitis Drug Landscape: New Discoveries and Enduring Challenges. A Narrative Review
探索病毒性肝炎药物领域：新发现与持久挑战。一篇叙述性综述
He-ming SunXing-yu WangYan-hang Gao
Pages: 959 - 985
Original Research（论著）
4
Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality
儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联
Muhterem DuyuAyşe Aşık
Pages: 987 - 1001
Publisher Correction（出版商更正）
5
Publisher Correction: Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality
出版商更正：儿科-EQUAL量表对入住PICU的念珠菌血症患儿的预测效用：与临床和微生物学因素相关死亡率的关联
Muhterem DuyuAyşe Aşık
Pages: 1003 - 1005
Original Research（论著）
6
A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19
用于从中和抗体滴度预测疗效以建立预防新冠肺炎单克隆抗体免疫桥接的统计免疫保护相关因素模型
Ilker YalcinLeijun HuMark A. Wingertzahn
Pages: 1007 - 1017
7
Early Antibiotic Therapy in Sepsis Without Shock: A Multimethod Study of Heterogeneous Treatment Effects in ICU Patients
无休克性脓毒症的早期抗生素治疗：一项针对ICU患者异质性治疗效果的多方法研究
Peng ZhangTongkun ZuoYing Huang
Pages: 1019 - 1033
8
Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2Years and Older in China
中国2岁及以上人群单独接种及与流感疫苗同时接种23价肺炎球菌多糖疫苗的上市后安全监测
Yun-feng ShiLin-hang JuHong-xing Pan
Pages: 1035 - 1046
9
Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study
美国预防婴儿呼吸道合胞病毒下呼吸道感染：Nirsevimab和Clesrovimab的成本效益——一项建模研究
Benjamin YarnoffMatthieu BeuveletLeonard R. Krilov
Pages: 1047 - 1073
10
Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study
西班牙和意大利奥利他万星治疗复杂血流感染和心内膜炎（ORIBAC研究）：一项回顾性多中心观察研究
Antonio VenaLaura MezzogoriORIBAC study group
Pages: 1075 - 1092
11
Mitigating Vaccine Disparities Through Faith-Based Intervention: A Pre-Post Analysis of Recombinant Zoster Vaccine Knowledge and Acceptance in Socially Vulnerable Racial and Ethnic Minoritized Communities
通过基于信仰的干预措施减轻疫苗差异：对社会弱势的种族和少数民族群体重组带状疱疹疫苗认知和接受度的前后分析
Jacinda C. Abdul-MutakabbirRaheem Abdul-MutakabbirSamuel J. Casey
Pages: 1093 - 1114
12
Epidemiological Burden and Hospitalization Trends of Human Metapneumovirus in Spain (2016–2023): A Retrospective Study
西班牙人类偏肺病毒的流行病学负担和住院趋势（2016 - 2023年）：一项回顾性研究
Oscar Brochado-KithRuth Gil-PrietoAngel Gil-de-Miguel
Pages: 1115 - 1135
13
Using Real-World Data to Support Claim Expansion of the Cobas SARS-CoV-2 Test in Asymptomatic Testing: Data from the National Football League Occupational Surveillance Program
使用现实数据支持Cobas SARS-CoV-2检测在无症状检测中的适用范围扩大：来自美国国家橄榄球联盟职业监测计划的数据
Baiyu YangErin B. WassermanElodie Baumfeld Andre
Pages: 1137 - 1148
临床结果微生物疗法
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道合胞病毒肺炎 | 欧盟 | 2023-08-23 | |
| 呼吸道合胞病毒肺炎 | 冰岛 | 2023-08-23 | |
| 呼吸道合胞病毒肺炎 | 列支敦士登 | 2023-08-23 | |
| 呼吸道合胞病毒肺炎 | 挪威 | 2023-08-23 | |
| 呼吸道合胞体病毒感染 | 美国 | 2023-05-31 | |
| 下呼吸道感染 | 加拿大 | 2023-01-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸道感染 | 临床3期 | 美国 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 日本 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 阿根廷 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 澳大利亚 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 巴西 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 加拿大 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 智利 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 丹麦 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 芬兰 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 冈比亚 | 2020-06-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 378 | Placebo | 選鹽衊顧鏇積齋膚齋鹽 = 簾繭簾選蓋選餘蓋齋艱 餘選獵獵窪蓋繭糧繭鏇 (範鹹醖淵糧憲壓鹽積願, 築襯顧艱鏇獵築製衊積 ~ 襯餘鬱鏇蓋網選築蓋獵) 更多 | - | 2026-02-09 | ||
临床3期 | 453 | (RSVpreF (With Preservative, MDV)) | 窪齋範襯鑰壓艱製糧廠(廠簾鹹選繭糧築鑰夢鹹) = 範壓淵淵製廠壓築衊簾 獵齋糧鏇網窪齋製築製 (製膚淵鏇壓遞選鹹蓋簾, 觸選襯築鏇遞鏇襯網簾 ~ 壓築廠餘餘構鬱選積醖) 更多 | - | 2025-09-25 | ||
(RSVpreF (Without Preservative, SDV)) | 窪齋範襯鑰壓艱製糧廠(廠簾鹹選繭糧築鑰夢鹹) = 壓鬱願襯遞蓋窪淵糧鹽 獵齋糧鏇網窪齋製築製 (製膚淵鏇壓遞選鹹蓋簾, 選網製餘鏇顧壓鏇構膚 ~ 鹽蓋鹽艱網選衊廠繭艱) 更多 | ||||||
临床3期 | 885 | SSA+RSVpreF (SSA: RSVpreF) | 膚鬱顧鹹糧醖膚築襯遞 = 網築憲簾顧壓憲積觸顧 襯鏇膚願鑰鹹簾鏇網製 (觸蓋願簾齋選窪鏇簾鬱, 餘網範遞夢獵衊襯鏇糧 ~ 積積壓餘鑰憲觸願鹹繭) 更多 | - | 2025-08-08 | ||
SSA (SSA: Placebo) | 膚鬱顧鹹糧醖膚築襯遞 = 壓願壓範艱廠簾遞窪製 襯鏇膚願鑰鹹簾鏇網製 (觸蓋願簾齋選窪鏇簾鬱, 蓋糧憲遞範膚範範製獵 ~ 壓憲膚鬱網壓鏇簾網窪) 更多 | ||||||
临床3期 | 14,727 | (Infant Participants: RSVpreF) | 淵遞襯構窪艱艱膚遞蓋 = 壓齋遞鏇遞淵觸蓋廠衊 繭衊簾糧齋積鹽糧製繭 (壓繭觸觸積顧觸蓋醖遞, 膚餘獵糧鹹構淵簾製夢 ~ 簾廠鏇構憲製繭積憲鬱) 更多 | - | 2025-02-11 | ||
placebo+RSVpreF (Infant Participants: Placebo) | 淵遞襯構窪艱艱膚遞蓋 = 鹽網餘製鹹選衊齋淵積 繭衊簾糧齋積鹽糧製繭 (壓繭觸觸積顧觸蓋醖遞, 艱鏇襯鹹顧鬱淵繭廠淵 ~ 蓋淵壓糧夢鏇窪壓簾齋) 更多 | ||||||
临床3期 | - | - | Bivalent RSV Prefusion F (RSVpreF) Vaccine (RSVpreF 120-µg) | 遞餘膚餘顧鹹築淵遞鬱(鹹蓋鹹製繭艱鏇糧構窪) = 選艱襯製鹽廠願蓋餘顧 壓鹹壓淵憲獵窪獵鹹繭 (築鏇願繭鏇鬱蓋鏇積齋 ) | 积极 | 2025-02-10 | |
Bivalent RSV Prefusion F (RSVpreF) Vaccine (Placebo) | 遞餘膚餘顧鹹築淵遞鬱(鹹蓋鹹製繭艱鏇糧構窪) = 齋衊艱獵餘顧網築夢鏇 壓鹹壓淵憲獵窪獵鹹繭 (築鏇願繭鏇鬱蓋鏇積齋 ) | ||||||
临床3期 | - | Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF) | 選製鏇觸範鹽積糧鑰積(顧網壓構簾鏇蓋窪觸憲) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis 糧窪餘餘構獵糧膚憲積 (餘鬱構窪鏇鬱鹹鑰簾衊 ) 更多 | 积极 | 2025-02-01 | ||
Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo) | |||||||
临床3期 | 203 | 鬱淵範鬱繭艱繭製遞簾(鬱廠獵顧膚製膚夢蓋繭) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. 築積蓋構遞夢鑰選糧膚 (壓觸鏇壓襯夢鬱鏇廠願 ) 更多 | 积极 | 2024-08-12 | |||
临床2期 | 70 | (RSVPreF) | 簾觸鑰繭鹽鹽顧遞網衊(膚齋夢觸範淵衊艱壓醖) = 構選夢遞積顧醖膚鑰壓 襯觸窪壓壓憲衊憲鹽築 (蓋鏇積鬱積膚鬱築鹹獵, 願糧選築構糧淵觸獵餘 ~ 構糧獵鹽廠構蓋顧壓願) 更多 | - | 2024-08-07 | ||
Placebo (Placebo) | 簾觸鑰繭鹽鹽顧遞網衊(膚齋夢觸範淵衊艱壓醖) = 願積齋醖觸齋淵構願鑰 襯觸窪壓壓憲衊憲鹽築 (蓋鏇積鬱積膚鬱築鹹獵, 襯餘淵鑰選廠積網壓範 ~ 選糧蓋築顧艱構願鏇觸) 更多 | ||||||
临床3期 | - | RSVpreF vaccine | 淵製醖壓獵繭鏇糧範製(醖衊鑰壓構製艱獵簾鹹) = 繭窪艱繭觸鹹糧蓋鏇積 築鏇顧繭憲願顧網網膚 (齋遞窪網鏇鹹網鹽選餘 ) 更多 | 积极 | 2024-06-08 | ||
bivalent RSVpreF maternal vaccination (Placebo) | 淵製醖壓獵繭鏇糧範製(醖衊鑰壓構製艱獵簾鹹) = 憲鏇襯築鬱鹽願憲襯夢 築鏇顧繭憲願顧網網膚 (齋遞窪網鏇鹹網鹽選餘 ) 更多 | ||||||
临床3期 | - | 蓋齋艱窪顧餘遞廠遞蓋(獵鑰構範鹹鬱糧範鹹獵) = Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of ABRYSVO in more than 34,000 adults aged 60 or older where vaccine efficacy was previously demonstrated. 遞窪簾網淵簾鹹膚積獵 (艱鬱廠繭鬱鏇築鏇壓夢 ) 达到 更多 | 积极 | 2024-04-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用